U.S. markets open in 33 minutes
  • S&P Futures

    3,606.00
    +30.00 (+0.84%)
     
  • Dow Futures

    29,876.00
    +330.00 (+1.12%)
     
  • Nasdaq Futures

    11,958.00
    +52.75 (+0.44%)
     
  • Russell 2000 Futures

    1,842.30
    +25.20 (+1.39%)
     
  • Crude Oil

    43.68
    +0.62 (+1.44%)
     
  • Gold

    1,806.00
    -31.80 (-1.73%)
     
  • Silver

    23.15
    -0.48 (-2.04%)
     
  • EUR/USD

    1.1869
    +0.0024 (+0.20%)
     
  • 10-Yr Bond

    0.8680
    +0.0110 (+1.28%)
     
  • Vix

    21.97
    -1.73 (-7.30%)
     
  • GBP/USD

    1.3329
    +0.0007 (+0.05%)
     
  • USD/JPY

    104.5860
    +0.0980 (+0.09%)
     
  • BTC-USD

    19,171.69
    +719.72 (+3.90%)
     
  • CMC Crypto 200

    377.91
    +16.48 (+4.56%)
     
  • FTSE 100

    6,412.27
    +78.43 (+1.24%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

BIIB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 12, 2021 in the Class Action Filed on Behalf of Biogen Inc. Limited Shareholders

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - November 20, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Biogen Inc. (NASDAQ: BIIB) alleging that the Company violated federal securities laws.

Class Period: October 22, 2019 and November 6, 2019
Lead Plaintiff Deadline: January 12, 2021

Learn more about your recoverable losses in BIIB:
http://www.kleinstocklaw.com/pslra-1/biogen-inc-loss-submission-form?id=11121&from=5

The filed complaint alleges that Biogen Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders have until January 12, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

For additional information about the BIIB lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68689